Efficacy and Safety of Cerivastatin, 0.2 mg and 0.4 mg, in Patients with Primary Hypercholesterolemia: a Multinational, Randomised, Double-blind Study

Authors:
  • OLOlavi Luurila
    Olavi Luurila
  • JEJ. Eriksson
    J. Eriksson
  • AOAnders Olsson
    Anders Olsson
  • BWBengt Widgren
    Bengt Widgren
  • OSon behalf of the Cerivastatin Study
    on behalf of the Cerivastatin Study

Abstract
SummaryElevated serum cholesterol level is a key risk factor for cardiovascular morbidity and mortality. Cerivastatin is a highly effective lipid-lowering agent currently licensed at doses of 0.1, 0.2, 0.3 and 0.4 mg.This was a multicentre, randomised, double-blind, parallel-group study comparing the efficacy and safety of cerivastatin OAmglday with that of cerivastatin 0.2 mg/day in patients with primary hypercholesterolemia. There was a six-week placebo run-in phase followed by a 24-week active treatment phase. A total of 494 patients were randomised to receive cerivastatin 0.4mg (n = 332) or 0.2mg (n = 162). Per-protocol (PP) analysis revealed that mean low-density lipoprotein cholesterol (LDL-C) level decreased by 38.4 ± 0.7% from baseline in the 0.4 mg group, compared with a decrease of 31.5 ± 0.9% in the 0.2mg group (p < 0.0001). There was a significant gender difference in the 0.4 mg group: LDL-C decreased by 44.4 ± 8.9% in women, compared with a decrease of 37.0 ± 0.9% in men (p < 0.046). In the P...

This publication has 9 references indexed in Scilit: